Alembic Pharmaceuticals Limited (APLLTD) - Total Assets

Latest as of September 2025: Rs83.97 Billion INR ≈ $908.10 Million USD

Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) holds total assets worth Rs83.97 Billion INR (≈ $908.10 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Alembic Pharmaceuticals Limited (APLLTD) net assets for net asset value and shareholders' equity analysis.

Alembic Pharmaceuticals Limited - Total Assets Trend (2011–2025)

This chart illustrates how Alembic Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data.

Alembic Pharmaceuticals Limited - Asset Composition Analysis

Current Asset Composition (March 2025)

Alembic Pharmaceuticals Limited's total assets of Rs83.97 Billion consist of 52.6% current assets and 47.4% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 1.2%
Accounts Receivable Rs14.00 Billion 18.0%
Inventory Rs22.88 Billion 29.4%
Property, Plant & Equipment Rs33.61 Billion 43.2%
Intangible Assets Rs0.00 0.0%
Goodwill Rs0.00 0.0%

Asset Composition Trend (2011–2025)

This chart illustrates how Alembic Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Alembic Pharmaceuticals Limited (APLLTD) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Alembic Pharmaceuticals Limited's current assets represent 52.6% of total assets in 2025, a decrease from 64.2% in 2011.
  • Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, up from 0.8% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
  • Asset Diversification: The largest asset category is property, plant & equipment at 43.2% of total assets.

Alembic Pharmaceuticals Limited Competitors by Total Assets

Key competitors of Alembic Pharmaceuticals Limited based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Alembic Pharmaceuticals Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.59 1.73 2.52
Quick Ratio 0.66 0.81 1.26
Cash Ratio 0.00 0.00 0.00
Working Capital Rs16.19 Billion Rs15.91 Billion Rs15.39 Billion

Alembic Pharmaceuticals Limited - Advanced Valuation Insights

This section examines the relationship between Alembic Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.94
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 20.6%
Total Assets Rs77.73 Billion
Market Capitalization $1.60 Billion USD

Valuation Analysis

Below Book Valuation: The market values Alembic Pharmaceuticals Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Alembic Pharmaceuticals Limited's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Alembic Pharmaceuticals Limited (2011–2025)

The table below shows the annual total assets of Alembic Pharmaceuticals Limited from 2011 to 2025.

Year Total Assets Change
2025-03-31 Rs77.73 Billion
≈ $840.61 Million
+20.59%
2024-03-31 Rs64.46 Billion
≈ $697.07 Million
+4.25%
2023-03-31 Rs61.83 Billion
≈ $668.65 Million
-13.19%
2022-03-31 Rs71.22 Billion
≈ $770.22 Million
+6.16%
2021-03-31 Rs67.09 Billion
≈ $725.55 Million
+12.02%
2020-03-31 Rs59.89 Billion
≈ $647.69 Million
+25.35%
2019-03-31 Rs47.78 Billion
≈ $516.70 Million
+21.23%
2018-03-31 Rs39.41 Billion
≈ $426.21 Million
+46.69%
2017-03-31 Rs26.87 Billion
≈ $290.55 Million
+9.24%
2016-03-31 Rs24.59 Billion
≈ $265.97 Million
+49.86%
2015-03-31 Rs16.41 Billion
≈ $177.49 Million
+34.76%
2014-03-31 Rs12.18 Billion
≈ $131.70 Million
+16.22%
2013-03-31 Rs10.48 Billion
≈ $113.32 Million
-0.39%
2012-03-31 Rs10.52 Billion
≈ $113.76 Million
+24.69%
2011-03-31 Rs8.44 Billion
≈ $91.24 Million
--

About Alembic Pharmaceuticals Limited

NSE:APLLTD India Drug Manufacturers - Specialty & Generic
Market Cap
$1.60 Billion
Rs148.41 Billion INR
Market Cap Rank
#7108 Global
#323 in India
Share Price
Rs755.00
Change (1 day)
-0.80%
52-Week Range
Rs646.55 - Rs1039.10
All Time High
Rs1247.70
About

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more